These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 8296408)

  • 1. [Adverse effects of subcutaneous administration of erythropoietin solution versus lyophilisate in patients receiving hemodialysis].
    Jensen GV; Nielsen B
    Ugeskr Laeger; 1994 Jan; 156(2):183-4. PubMed ID: 8296408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion from subcutaneous to intravenous erythropoietin in a hemodialysis population.
    Vercaigne LM; Collins DM; Penner SB
    J Clin Pharmacol; 2005 Aug; 45(8):895-900. PubMed ID: 16027399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pain at the injection site of subcutaneously administered erythropoietin: phosphate-buffered epoetin alpha compared to citrate-buffered epoetin alpha and epoetin beta.
    Veys N; Dhondt A; Lameire N
    Clin Nephrol; 1998 Jan; 49(1):41-4. PubMed ID: 9491285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythropoietin dose requirements when converting from subcutaneous to intravenous administration among patients on hemodialysis.
    Moist LM; Muirhead N; Wazny LD; Gallo KL; Heidenheim AP; House AA
    Ann Pharmacother; 2006 Feb; 40(2):198-203. PubMed ID: 16449549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the efficacy of measures to reduce pain after subcutaneous administration of epoetin alfa.
    Frenken LA; van Lier HJ; Koene RA
    Nephrol Dial Transplant; 1994; 9(9):1295-8. PubMed ID: 7816293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F; David S; Sala P; Icardi A; Casani A
    Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
    Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
    Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biocompatibility and permeability of dialyzer membranes do not affect anemia, erythropoietin dosage or mortality in japanese patients on chronic non-reuse hemodialysis: a prospective cohort study from the J-DOPPS II study.
    Yokoyama H; Kawaguchi T; Wada T; Takahashi Y; Higashi T; Yamazaki S; Fukuhara S; Akiba T; Akizawa T; Asano Y; Kurokawa K; Saito A;
    Nephron Clin Pract; 2008; 109(2):c100-8. PubMed ID: 18596379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB; Dowell JA; Pratt RD
    Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.
    Vincent JL; Spapen HD; Creteur J; Piagnerelli M; Hubloue I; Diltoer M; Roman A; Stevens E; Vercammen E; Beaver JS
    Crit Care Med; 2006 Jun; 34(6):1661-7. PubMed ID: 16607233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of pain after subcutaneous injection of erythropoietin in patients receiving haemodialysis.
    Frenken LA; van Lier HJ; Gerlag PG; den Hartog M; Koene RA
    BMJ; 1991 Aug; 303(6797):288. PubMed ID: 1888931
    [No Abstract]   [Full Text] [Related]  

  • 12. [Effects of subcutaneous administration of erythropoietin on autologous blood predonation in open heart surgery: Japanese multicenter double-blinded dose-study].
    Omoto R; Kyo S; Furuse A; Hosoda Y; Eguchi S; Matsuda H; Kito Y; Hirashima K; Ogawa N
    Rinsho Kyobu Geka; 1994 Dec; 14(6):510-21. PubMed ID: 9423132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching from subcutaneous to intravenous erythropoietin alpha in haemodialysis patients requires a major dose increase.
    Galliford JW; Malasana R; Farrington K
    Nephrol Dial Transplant; 2005 Sep; 20(9):1956-62. PubMed ID: 15930017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients.
    El-Khatib M; Duncan HJ; Kant KS
    Nephrology (Carlton); 2006 Oct; 11(5):400-4. PubMed ID: 17014552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin.
    Markowitz GS; Kahn GA; Feingold RE; Coco M; Lynn RI
    Clin Nephrol; 1997 Jul; 48(1):34-40. PubMed ID: 9247776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of advanced kidney cancer using recombinant erythropoietin].
    Morere JF; Bouillet T; Piperno-Neumann S; Tourani JM; Brunet A; Hennebelle F; Bareau JL
    Prog Urol; 1997 Jun; 7(3):399-402. PubMed ID: 9273066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Correction of anemia in hemodialysis, effect of intravenous iron without erythropoietin].
    Alvo M; Elgueta L; Aragón H; Cotera A
    Rev Med Chil; 2002 Aug; 130(8):865-8. PubMed ID: 12360794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another.
    Macdougall IC
    Curr Med Res Opin; 2004 Jan; 20(1):83-6. PubMed ID: 14741076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.